Johnson & Johnson (NYSE:JNJ) Stock News, Headlines & Updates
Johnson & Johnson Stock News from GuruFocus
- 1
- 2
- 3
- 4
Jun 27, 2025
Johnson & Johnson (JNJ) Pauses Laminar LAAX IDE Trial for Review | JNJ Stock News
GuruFocus News • 12:45pm
Jun 23, 2025
Johnson & Johnson (JNJ) Introduces Revolutionary Contact Lens | JNJ Stock News
GuruFocus News • 12:23pm
Johnson & Johnson (JNJ) Showcases Promising Data for IMAAVY in Myasthenia Gravis | JNJ Stock News
GuruFocus News • 12:18pm
Johnson & Johnson (JNJ) Reports Positive Results for Imaavy in Myasthenia Gravis Study
GuruFocus News • 8:57am
IMAAVYâ„¢ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published indire
GuruFocus News • 6:45am
Jun 20, 2025
Johnson & Johnson (JNJ) Gains EU Backing for Imbruvica Label Expansion
GuruFocus News • 9:55am
Jun 18, 2025
Johnson & Johnson (JNJ) Ordered to Pay $8M in Mesothelioma Talc Case | JNJ Stock News
GuruFocus News • 6:15pm
Johnson & Johnson Hit With $8M Verdict in Massachusetts Mesothelioma Talc Lawsuit | JNJ Stock News
GuruFocus News • 6:00pm
Jun 17, 2025
Pharmaceutical Stocks React as Trump Plans New Tariffs
GuruFocus News • 6:55am
Jun 16, 2025
Bullish Momentum for Johnson & Johnson (JNJ) as Call Options Surge | JNJ Stock News
GuruFocus News • 11:15am
Johnson & Johnson (JNJ) Reports Promising Phase 2 Study Results for Multiple Myeloma Treatment | JNJ Stock News
GuruFocus News • 7:45pm
Jun 15, 2025
Johnson & Johnson's Phase 2 Study Shows Promising Results for Multiple Myeloma Treatment | JNJ stock news
GuruFocus News • 3:00am
Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease
PRNewswire • 3:00am
Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease | JNJ Stock
GuruFocus News • 2:30am
Jun 13, 2025
Johnson & Johnson's (JNJ) CAR T-cell Therapy Shows Promising Results in Trials
GuruFocus News • 1:57pm
Johnson & Johnson's Dual-Targeting CAR T-Cell Therapy Shows Promising Results in Large B-Cell Lymphoma | JNJ stock news
GuruFocus News • 12:01pm
Johnson & Johnson's dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma
PRNewswire • 11:00am
Johnson & Johnson (JNJ) Reveals Promising Data for Dual-Targeting CAR T-Cell Therapy | JNJ Stock News
GuruFocus News • 10:30am
Johnson & Johnson's dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma | JNJ Stock News
GuruFocus News • 10:15am
Jun 12, 2025
Johnson & Johnson's Bleximenib Shows Promising Results in AML Treatment | JNJ stock news
GuruFocus News • 12:04pm
Johnson & Johnson (JNJ) Discussed in Prostate Cancer Treatment Conference | JNJ Stock News
GuruFocus News • 11:00am
New results for Johnson & Johnson's bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia
PRNewswire • 11:00am
Johnson & Johnson (JNJ) Phase 1b Study Shows Promise for Leukemia Treatment
GuruFocus News • 10:56am
Johnson & Johnson (JNJ) Demonstrates Promising Results in AML Treatment Study | JNJ Stock News
GuruFocus News • 10:30am
New results for Johnson & Johnson's bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia | JNJ Stock News
GuruFocus News • 10:15am
Jun 11, 2025
Johnson & Johnson's TREMFYA® Shows Promising Results in Psoriatic Arthritis Treatment | JNJ stock news
GuruFocus News • 8:06am
New data show TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis
PRNewswire • 8:00am
JNJ's TREMFYA Shows Promising Results in Psoriatic Arthritis Study | JNJ Stock News
GuruFocus News • 7:34am
New data show TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis | JNJ Stock News
GuruFocus News • 7:15am
Jun 10, 2025
Johnson & Johnson (JNJ) Announces New Board Appointment
GuruFocus News • 6:30pm
Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors | JNJ Stock News
GuruFocus News • 4:15pm
Johnson & Johnson Welcomes Daniel Pinto to Board of Directors | JNJ stock news
GuruFocus News • 4:07pm
Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors
Business Wire • 4:00pm
Jun 05, 2025
Johnson & Johnson (JNJ) Stock Rating Reiterated by RBC Capital | JNJ Stock News
GuruFocus News • 10:00am
Jun 04, 2025
Johnson & Johnson (JNJ) Backs Promising Myeloma Treatment Study | JNJ Stock News
GuruFocus News • 9:16am
Jun 03, 2025
Johnson & Johnson's Darzalex Faspro Shows Promising Results in Myeloma Studies | JNJ Stock News
GuruFocus News • 10:15am
Early results from Johnson & Johnson's trispecific antibody show promising response in heavily pretreated multiple myeloma patients | JNJ Stock News
GuruFocus News • 10:01am
Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma | JNJ Stock News
GuruFocus News • 10:01am
- 1
- 2
- 3
- 4
Show
Entries
Headlines
Total 0- 1
No recent news